TY - JOUR T1 - Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for <em>Mycobacterium tuberculosis</em> JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02215-2016 VL - 49 IS - 4 SP - 1602215 AU - Donald G. Catanzaro AU - Andre P. Trollip AU - Marva Seifert AU - Sophia B. Georghiou AU - Richard S. Garfein AU - Timothy C. Rodwell AU - Antonino Catanzaro AU - Kathleen D. Eisenach Y1 - 2017/04/01 UR - http://erj.ersjournals.com/content/49/4/1602215.abstract N2 - The End Tuberculosis Strategy of the World Health Organization (WHO) calls for the early diagnosis of tuberculosis (TB) and use of universal drug susceptibility testing (DST) in order to start patients on the most effective treatment regimen as early as possible. DST using solid or liquid media and rapid molecular-based DST to detect drug-resistant TB are available and endorsed by WHO; however, in 2015, WHO reported that among new cases of bacteriologically confirmed TB, only 12% had undergone DST [1]. Most national tuberculosis programmes do not offer universal DST [2], and in 2015, 12 countries reported no capacity to perform phenotypic DST [1] while 28 countries had neither in-country capacity nor a linkage with a partner laboratory for second-line DST.A new multinational study of the noncommercial MODS assay shows excellent performance in detecting M/XDR-tuberculosis http://ow.ly/FAEJ308OiOwThe authors would like to acknowledge the site investigators, Valeriu Crudu (Phthisiopneumology Institute), Tommie Victor (Stellenbosch University) and Camilla Rodriques (P.D. Hinduja National Hospital and Medical Research Centre), as well as their clinical and laboratory staff for their assistance in acquiring and testing patient specimens. ER -